<b>Patients and Methods:</b> We evaluated the efficacy of the CTLA-4 targeted agent, ipilimumab, in metastatic prostate cancer patients who had an incomplete biochemical response to initial androgen deprivation therapy (ADT) alone. Here, CTLA4 is linked to metastatic prostate carcinoma.